Gilead Sciences (GILD) News 68.55 $GILD
Most active Nasdaq-traded stocks
AP - Fri Mar 28, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Final Glance: Biotechnology companies
AP - Fri Mar 28, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
After Yesterday's Decline of 4.01%, Gilead Sciences Offers Investors Better Value
Comtex SmarTrend(R) - Fri Mar 28, 3:40PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $67.63 to a high of $71.11. Yesterday, the shares fell 4.0%, which took the trading range below the 3-day low of $70.59 on volume of 29.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Gilead Sciences Falls 4.01% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Mar 28, 3:40PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $67.63 to a high of $71.11. Yesterday, the shares fell 4.0%, which took the trading range below the 3-day low of $70.59 on volume of 29.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Why Gilead Sciences (GILD) Stock Was Down Today
at The Street - Fri Mar 28, 3:27PM CDT
Shares of Gilead Sciences (GILD) closed down 4.0% to $68.55 in trading Friday.
Poof! Biotech's 2014 Outperformance is Gone
at The Street - Fri Mar 28, 3:16PM CDT
Biotech stocks continue to melt down. I know, broken record, but like a car wreck, it's hard not to look.
Today's Roof Leaker Stock Is Gilead (GILD)
at The Street - Fri Mar 28, 1:37PM CDT
Trade-Ideas LLC identified Gilead (GILD) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
Rebound Rally Losing More Steam; BitAuto Hangs Tough
at Investor's Business Daily - Fri Mar 28, 1:36PM CDT
Rebound efforts greatly faded late Friday, leaving stocks in mixed territory and on pace for weekly losses. The Nasdaq lost 0.1% after rising as much as 1.3% intraday. The S&P 500 rose 0.2%, down from 1% at its session peak. Meanwhile, the Dow Jones...
Update on Glaxo's Mekinist-Tafinlar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:30PM CDT
GlaxoSmithKline came out with disappointing news regarding its Tafinlar-Mekinist combination for BRAF V600 E or K mutation-positive unresectable or metastatic melanoma.
CONSOL Energy Is the Champion This March
Taylor Muckerman and Alison Southwick, The Motley Fool - Motley Fool - Fri Mar 28, 12:47PM CDT
In the final round match-up of The Motley Fool Better-Buy Tournament, CONSOL Energy bested Universal Display by a healthy margin it its battle to determine which stock is the better buy now. The 64-company tournament pitted two Motley Fool...
Midday Glance: Biotechnology companies
AP - Fri Mar 28, 12:32PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Gilead's HCV Candidate Under Review in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 10:40AM CDT
Gilead's combination HCV therapy is under review in the EU.
Early Glance: Biotechnology companies
AP - Fri Mar 28, 9:22AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Dow 30 Stock Roundup: Pfizer Gains, Crimea, Biotech Stocks Drag Markets - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Mar 28, 8:55AM CDT
The Dow has had a poor run this week, primarily due to a selloff in biotech stocks and the resurgence of concerns over Crimea.
Gilead Announces Settlement Method for 1.00% Convertible Senior Notes Due 2014
Business Wire - Fri Mar 28, 7:30AM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has elected to settle its conversion obligations in connection with any 1.00% Senior Convertible Notes due 2014 (the "Notes") submitted for conversion on or after February 1, 2014 entirely in cash.
Gilead's Marketing Application Validated by EMA; Accenture Misses Zack's Consensus Estimate
ACCESSWIRE - Thu Mar 27, 11:38PM CDT
Accenture plc (NYSE: ACN) - For an in-depth report on Accenture plc follow: www.BullTrends.com/stockquote/ACN
Glaxo's Eperzan Approved in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 6:00PM CDT
GlaxoSmithKline's diabetes drug, Eperzan, gained approval in the EU.
GILEAD SCIENCES'
at Investor's Business Daily - Thu Mar 27, 5:51PM CDT
GILEAD SCIENCES' (GILD) once-daily hepatitis C combo-drug treatment will get an accelerated review by European regulators. Shares edged higher.
Insmed Down on Disappointing Arikayce Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 4:48PM CDT
Insmed shares skid over 13% after the company announced that Arikayce failed to meet the primary objective.
Most active Nasdaq-traded stocks
AP - Fri Mar 28, 5:02PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Final Glance: Biotechnology companies
AP - Fri Mar 28, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
After Yesterday's Decline of 4.01%, Gilead Sciences Offers Investors Better Value
Comtex SmarTrend(R) - Fri Mar 28, 3:40PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $67.63 to a high of $71.11. Yesterday, the shares fell 4.0%, which took the trading range below the 3-day low of $70.59 on volume of 29.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Gilead Sciences Falls 4.01% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Mar 28, 3:40PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $67.63 to a high of $71.11. Yesterday, the shares fell 4.0%, which took the trading range below the 3-day low of $70.59 on volume of 29.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Why Gilead Sciences (GILD) Stock Was Down Today
at The Street - Fri Mar 28, 3:27PM CDT
Shares of Gilead Sciences (GILD) closed down 4.0% to $68.55 in trading Friday.
Poof! Biotech's 2014 Outperformance is Gone
at The Street - Fri Mar 28, 3:16PM CDT
Biotech stocks continue to melt down. I know, broken record, but like a car wreck, it's hard not to look.
Today's Roof Leaker Stock Is Gilead (GILD)
at The Street - Fri Mar 28, 1:37PM CDT
Trade-Ideas LLC identified Gilead (GILD) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
Rebound Rally Losing More Steam; BitAuto Hangs Tough
at Investor's Business Daily - Fri Mar 28, 1:36PM CDT
Rebound efforts greatly faded late Friday, leaving stocks in mixed territory and on pace for weekly losses. The Nasdaq lost 0.1% after rising as much as 1.3% intraday. The S&P 500 rose 0.2%, down from 1% at its session peak. Meanwhile, the Dow Jones...
Update on Glaxo's Mekinist-Tafinlar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:30PM CDT
GlaxoSmithKline came out with disappointing news regarding its Tafinlar-Mekinist combination for BRAF V600 E or K mutation-positive unresectable or metastatic melanoma.
CONSOL Energy Is the Champion This March
Taylor Muckerman and Alison Southwick, The Motley Fool - Motley Fool - Fri Mar 28, 12:47PM CDT
In the final round match-up of The Motley Fool Better-Buy Tournament, CONSOL Energy bested Universal Display by a healthy margin it its battle to determine which stock is the better buy now. The 64-company tournament pitted two Motley Fool...
Midday Glance: Biotechnology companies
AP - Fri Mar 28, 12:32PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Gilead's HCV Candidate Under Review in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 10:40AM CDT
Gilead's combination HCV therapy is under review in the EU.
Early Glance: Biotechnology companies
AP - Fri Mar 28, 9:22AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Dow 30 Stock Roundup: Pfizer Gains, Crimea, Biotech Stocks Drag Markets - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Mar 28, 8:55AM CDT
The Dow has had a poor run this week, primarily due to a selloff in biotech stocks and the resurgence of concerns over Crimea.
Gilead Announces Settlement Method for 1.00% Convertible Senior Notes Due 2014
Business Wire - Fri Mar 28, 7:30AM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has elected to settle its conversion obligations in connection with any 1.00% Senior Convertible Notes due 2014 (the "Notes") submitted for conversion on or after February 1, 2014 entirely in cash.
Gilead's Marketing Application Validated by EMA; Accenture Misses Zack's Consensus Estimate
ACCESSWIRE - Thu Mar 27, 11:38PM CDT
Accenture plc (NYSE: ACN) - For an in-depth report on Accenture plc follow: www.BullTrends.com/stockquote/ACN
Glaxo's Eperzan Approved in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 6:00PM CDT
GlaxoSmithKline's diabetes drug, Eperzan, gained approval in the EU.
GILEAD SCIENCES'
at Investor's Business Daily - Thu Mar 27, 5:51PM CDT
GILEAD SCIENCES' (GILD) once-daily hepatitis C combo-drug treatment will get an accelerated review by European regulators. Shares edged higher.
Insmed Down on Disappointing Arikayce Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 4:48PM CDT
Insmed shares skid over 13% after the company announced that Arikayce failed to meet the primary objective.
